- Home
- CNTA vs ADPT Comparison
CNTA vs ADPT Comparison
Compare CNTA & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- ADPT
- Stock Information
- Founded
- CNTA 2020
- ADPT 2009
- Country
- CNTA United Kingdom
- ADPT United States
- Employees
- CNTA N/A
- ADPT N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNTA Health Care
- ADPT Health Care
- Exchange
- CNTA Nasdaq
- ADPT Nasdaq
- Market Cap
- CNTA 2.3B
- ADPT 2.6B
- IPO Year
- CNTA 2021
- ADPT 2019
- Fundamental
- Price
- CNTA $22.92
- ADPT $15.69
- Analyst Decision
- CNTA Strong Buy
- ADPT Strong Buy
- Analyst Count
- CNTA 9
- ADPT 10
- Target Price
- CNTA $31.75
- ADPT $15.70
- AVG Volume (30 Days)
- CNTA 1.3M
- ADPT 1.6M
- Earning Date
- CNTA 11-05-2025
- ADPT 11-05-2025
- Dividend Yield
- CNTA N/A
- ADPT N/A
- EPS Growth
- CNTA N/A
- ADPT N/A
- EPS
- CNTA N/A
- ADPT N/A
- Revenue
- CNTA $15,000,000.00
- ADPT $252,754,000.00
- Revenue This Year
- CNTA N/A
- ADPT $36.43
- Revenue Next Year
- CNTA N/A
- ADPT $12.31
- P/E Ratio
- CNTA N/A
- ADPT N/A
- Revenue Growth
- CNTA 118.88
- ADPT 42.57
- 52 Week Low
- CNTA $9.60
- ADPT $4.27
- 52 Week High
- CNTA $25.42
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- CNTA 48.74
- ADPT 45.74
- Support Level
- CNTA $17.05
- ADPT $16.51
- Resistance Level
- CNTA $25.35
- ADPT $17.75
- Average True Range (ATR)
- CNTA 1.47
- ADPT 0.88
- MACD
- CNTA -0.21
- ADPT -0.20
- Stochastic Oscillator
- CNTA 71.72
- ADPT 6.78
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).